GeneFerm Biotechnology Co Ltd (1796) - Cash Flow Conversion Efficiency
Based on the latest financial reports, GeneFerm Biotechnology Co Ltd (1796) has a cash flow conversion efficiency ratio of 0.002x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$1.45 Million ≈ $45.65K USD) by net assets (NT$794.03 Million ≈ $25.02 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of GeneFerm Biotechnology Co Ltd for the company's overall valuation and market capitalisation.
GeneFerm Biotechnology Co Ltd - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how GeneFerm Biotechnology Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
GeneFerm Biotechnology Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GeneFerm Biotechnology Co Ltd ranked by their cash flow conversion efficiency. Explore GeneFerm Biotechnology Co Ltd cash earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Autech Corporation
KQ:067170
|
-0.009x |
|
Fokus Mining Corp
V:FKM
|
-0.026x |
|
Wisher Industrial Co Ltd
TW:1465
|
-0.178x |
|
Suzhou QingYue Optoelectronics Technology Co. Ltd. A
SHG:688496
|
N/A |
|
Taekyung Chem
KO:006890
|
0.014x |
|
KWANGJIN WINTEC CO. Ltd
KQ:090150
|
0.079x |
|
Mountain Crest Acquisition Corp V
NASDAQ:MCAG
|
0.027x |
|
Carnegie Clean Energy Limited
F:CNM1
|
-0.027x |
Annual Cash Flow Conversion Efficiency for GeneFerm Biotechnology Co Ltd (2017–2024)
The table below shows the annual cash flow conversion efficiency of GeneFerm Biotechnology Co Ltd from 2017 to 2024. View current stock price of GeneFerm Biotechnology Co Ltd for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$788.18 Million ≈ $24.83 Million |
NT$8.09 Million ≈ $254.88K |
0.010x | -95.18% |
| 2023-12-31 | NT$892.84 Million ≈ $28.13 Million |
NT$190.31 Million ≈ $6.00 Million |
0.213x | +44.64% |
| 2022-12-31 | NT$830.77 Million ≈ $26.17 Million |
NT$122.43 Million ≈ $3.86 Million |
0.147x | -1.82% |
| 2021-12-31 | NT$747.66 Million ≈ $23.56 Million |
NT$112.23 Million ≈ $3.54 Million |
0.150x | +5.41% |
| 2020-12-31 | NT$396.19 Million ≈ $12.48 Million |
NT$56.42 Million ≈ $1.78 Million |
0.142x | +825.46% |
| 2019-12-31 | NT$954.50 Million ≈ $30.07 Million |
NT$14.69 Million ≈ $462.72K |
0.015x | -84.79% |
| 2018-12-31 | NT$416.51 Million ≈ $13.12 Million |
NT$42.14 Million ≈ $1.33 Million |
0.101x | -47.83% |
| 2017-12-31 | NT$314.95 Million ≈ $9.92 Million |
NT$61.08 Million ≈ $1.92 Million |
0.194x | -- |
About GeneFerm Biotechnology Co Ltd
GeneFerm Biotechnology Co., Ltd. develops, manufactures, and sells fermented health products in Taiwan and internationally. The company offers microbial fermentation products, including fungi, bacteria, lactic acid bacteria, yeast, algae, etc.; bio fermented ingredients, such as nattomena, natto fermented powder, red yeast rice fermented powder, antrodia cinnamomea mycelia powder, cordyceps, reis… Read more